Sign in

    Shishi Jin

    Senior Analyst at Macquarie Group

    Shishi Jin is a Senior Analyst at Macquarie Group, specializing in U.S. biotechnology equity research with a focus on both large- and mid-cap names across the biotech industry. She covers a portfolio of key biopharmaceutical companies such as Amgen, Regeneron, and Gilead Sciences, and her research has been recognized for its depth and prescient investment calls, with a documented success rate above 63% and average return per rating of 16.6% according to TipRanks. Jin began her analyst career after earning her Ph.D. in Pharmacology and bringing scientific rigor to her investment analysis, joining Macquarie in 2019 following experience as a research associate and senior associate at Citigroup and Wells Fargo Securities. She holds FINRA Series 7, 63, 86, and 87 licenses, and has earned industry accolades for the accuracy and performance of her stock recommendations.

    Shishi Jin's questions to ECARX Holdings (ECX) leadership

    Shishi Jin's questions to ECARX Holdings (ECX) leadership • Q2 2024

    Question

    Shishi Jin from Macquarie asked about the primary drivers of the 40% hardware sales growth, the largest product segment contributing to it, and any new targets for total vehicles equipped with ECARX technology. She also inquired about the overseas market strategy, competitive landscape, and how ECARX is addressing geopolitical risks related to auto software.

    Answer

    CFO Phil Zhou and COO Peter Cirino explained that robust hardware growth was driven by successful global vehicle launches like the Volvo EX30 and Polestar 4. Qualcomm-based solutions still constitute about 80% of hardware revenue, with the Antora series growing to nearly 20%. Regarding geopolitical risks, Peter Cirino stated that ECARX's strategy involves significant investment in local European operations and engineering teams, which they started four years ago, to build local relationships and globalize their technology stack, thereby mitigating country-specific concerns.

    Ask Fintool Equity Research AI